MarketScreener Reports Positive Outcome of Breast Cancer Drug Trial Conducted by Novartis

On Monday, Novartis AG announced that a study assessing the effectiveness of the breast cancer medication Kisqali has achieved its main objective during a preliminary analysis.

According to the company, the medication has been proven to considerably decrease the chance of relapse in patients with specific early breast cancers who are susceptible to experiencing a recurrence. This is achieved through combining the drug with an endocrine treatment.

Novartis has announced that the Phase 3 trial, known as Natalee, has been terminated ahead of schedule after successfully fulfilling its primary objective.

Feel free to send a message to Cecilia Butini by email at [email protected].

The article is coming to a close, as reported by Dow Jones Newswires.